Calcitonin, a hormone that lowers calcium levels in the blood and prevents bone loss, has only been available in an injectable and nasally-administered format to date. New research by Conway investigator, Dr David Brayden promises to ultimately deliver an oral method of treating osteoporosis patients with this hormone, which would have many advantages over current treatment regimes.
All drugs taken orally face the same problem; they must get from the gut into the bloodstream and avoid being broken down by enzymes before they can carry out their job. This is no mean task for many drugs, but it is especially problematic for peptides, some of the main products of the pharmaceutical industry. Dr David Brayden, who is based in the Faculty of Veterinary Medicine, University College Dublin has suggested a method for delivering calcitonin into the bloodstream by the oral route. The research involves attaching calcitonin to a novel sticky polymer and incorporating components that will both prevent the breakdown of calcitonin and help it move across the gut wall.
Science Foundation Ireland recently awarded Dr Brayden substantial funding under their investigator programme grant scheme to develop his research. Dr. Brayden was formerly a senior research scientist with Elan Corporation before moving to University College Dublin in 2001.
Elaine Quinn | alfa
Usher syndrome: Gene therapy restores hearing and balance
25.09.2017 | Institut Pasteur
MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer
25.09.2017 | Case Western Reserve University
Graphene is up to the job
A warming planet
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
26.09.2017 | Life Sciences
26.09.2017 | Physics and Astronomy
26.09.2017 | Information Technology